Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal CancerBusiness Wire • 11/15/24
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid TumorsBusiness Wire • 11/15/24
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts sayMarket Watch • 11/12/24
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)Seeking Alpha • 11/11/24
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?Zacks Investment Research • 11/11/24
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trialMarket Watch • 11/11/24
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesBenzinga • 11/11/24
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024Business Wire • 11/11/24
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market SetbacksBenzinga • 11/08/24
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains24/7 Wall Street • 11/02/24
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024Business Wire • 10/31/24
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS ViewZacks Investment Research • 10/31/24
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/31/24